During the past decade, Okayama City General Medical Center Okayama City Hospital conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 2 clinical trials were completed, i.e. on average, 15.4% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 2 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Okayama City General Medical Center Okayama City Hospital" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Celgene" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Bayer" with 1 trials sponsored and "Daiichi Sankyo Co., Ltd." with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Okayama City General Medical Center Okayama City Hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Dermira, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Okayama City General Medical Center Okayama City Hospital" are "Covid19" (2 trials), "Heart Failure" (2 trials), "Myelodysplastic Syndromes" (2 trials), "Arthritis" (1 trials) and "Atopic Dermatitis" (1 trials). Many other conditions were trialed in "Okayama City General Medical Center Okayama City Hospital" in a lesser frequency.

Most popular intervention types in "Okayama City General Medical Center Okayama City Hospital" are "Drug" (12 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Empagliflozin" (2 trials), "Luspatercept" (2 trials), "Apixaban" (1 trials) and "Apixaban matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Okayama City General Medical Center Okayama City Hospital" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Okayama City General Medical Center Okayama City Hospital". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Okayama City General Medical Center Okayama City Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Okayama City General Medical Center Okayama City Hospital, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".